Artivion Inc AORT

NYS: AORT | ISIN: US2289031005   31/05/2024
23,60 USD (-1,05%)
(-1,05%)   31/05/2024

6 mei 2024 · Artivion Reports First Quarter 2024 Financial Results · Persbericht

29 april 2024 · Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting · Persbericht

22 april 2024 · Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results · Persbericht

1 april 2024 · Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference · Persbericht

6 maart 2024 · Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference · Persbericht

15 februari 2024 · Artivion Reports Fourth Quarter and Full Year 2023 Financial Results · Persbericht

1 februari 2024 · Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results · Persbericht

29 januari 2024 · Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting · Persbericht

18 januari 2024 · Artivion Obtains $350 Million in Senior Secured Credit Facilities · Persbericht

6 december 2023 · Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer · Persbericht

9 november 2023 · Artivion Announces Completion of Enrollment in PERSEVERE Trial · Persbericht

8 november 2023 · Artivion to Participate in Upcoming Investor Conferences · Persbericht

2 november 2023 · Artivion Reports Third Quarter 2023 Financial Results · Persbericht

19 oktober 2023 · Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results · Persbericht

5 oktober 2023 · Artivion Announces Presentation of Real World Data from Post Market Study of On-X® Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin · Persbericht

5 oktober 2023 · Artivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting · Persbericht

26 september 2023 · Artivion to Present at the Deutsche Bank 31st Annual Leveraged Finance Conference · Persbericht

14 september 2023 · Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase · Persbericht

3 augustus 2023 · Artivion Reports Second Quarter 2023 Financial Results · Persbericht

1 augustus 2023 · Artivion to Participate in Upcoming Investor Conferences · Persbericht

Mijn selecties